Disparities in Immunotherapy Use Prior to First-Line Approval for Metastatic Hepatocellular Carcinoma in the United States

Background/Objectives: Treatment options for advanced HCC are limited. Immunotherapy, a promising new therapeutic, has recently been incorporated as a first-line systemic treatment. This study evaluates immunotherapy uptake and disparities in its adoption prior to first-line approval, which are curr...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Manav Shah, Abdullah Khalid, Oliver Standring, Neda Amini, Lyudmyla Demyan, Shruti Koti, Emma Gazzara, Grace Wu, Nandan Vithlani, Danielle DePeralta, Sepideh Gholami, Matthew Weiss
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	MDPI AG 2025-02-01
Σειρά:	Onco
Θέματα:	immunotherapy hepatocellular carcinoma disparities NCDB
Διαθέσιμο Online:	https://www.mdpi.com/2673-7523/5/1/6
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!